(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/086101 A2

(51) International Patent Classification[7]: C12N 1/16

(21) International Application Number: PCT/BE02/00064

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

01870088.0	24 April 2001 (24.04.2001)	EP
60/305,604	17 July 2001 (17.07.2001)	US

(71) Applicant *(for all designated States except US)*: **INNOGENETICS N.V.** [BE/BE]; Intellectual Property Department, Technologiepark 6, B-9052 Ghent (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DEPLA, Erik** [BE/BE]; Burgstraat 58, B-9070 Destelbergen (BE). **BOSMAN, Alfons** [BE/BE]; Hulst 165, B-1745 Opwijk (BE). **DESCHAMPS, Geert** [BE/BE]; Ganzeplas 31, B-9880 Aalter (BE). **SABLON, Erwin** [BE/BE]; Robbroeklaan 1a, B-1785 Merchtem (BE). **SUCKOW, Manfred** [DE/DE]; Urdenbacher Dorfstr. 35, 40593 Düsseldorf (DE). **SAMSON, Isabelle** [BE/BE]; t'Ranke Riet 9, B-8501 Heule (BE). **VERHEYDEN, Gert** [BE/BE]; Dellestraat 45, B-3220 Holsbeek (BE).

(74) Common Representative: **INNOGENETICS N.V.**; Intellectual Property Department, Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/086101 A2

(54) Title: CORE-GLYCOSYLATED HCV ENVELOPE PROTEINS

(57) Abstract: The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80 % of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70 % are glycosylated with an oligomannose containing 8 to 10 mannoses. Furthermore, the ratio of the oligomannoses with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10 % of the oligomannoses is terminated with an α1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a *Hansenula* cell.